PeptidePros

Compare · Head-to-head

Epitalon vs Selank.

Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.

Which should you research first?

Start with Selank, then use the table to confirm fit.

Selank is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.

Comparison next step

Personalize this head-to-head.

Take the quiz before converting a comparison into a compound, vendor, or protocol decision.

01· Subject

Epitalon

Pineal tetrapeptide discussed in aging literature for melatonin/circadian and telomerase pathways. Evidence gaps significant.

Tier C-Dhigh risk

02· Subject

Selank

Tuftsin analogue peptide with anxiolytic/nootropic research and limited clinical GAD data.

Tier B-Cmed-high risk

01 · At a glance

Decision factorEpitalonSelank
Primary fitlongevity & anti-aging and sleep & relaxation comparisonscognitive & neuroprotection and sleep & relaxation comparisons
EvidenceTier C-DTier B-C
Riskhighmed-high
Experience leveladvancedintermediate
Budget tiermidmid
Administration routesubcutaneous, intramuscular, intranasalintranasal

02 · Use case & timing

Decision factorEpitalonSelank
Goal fitLongevity & Anti-Aging, Sleep & RelaxationCognitive & Neuroprotection, Sleep & Relaxation, Anxiety & Mood
What users compare it forLongevity/circadian claims; telomerase association not established as fact.Anxiolytic/calm focus effects reported in limited clinical settings.
Onset timelineOften marketed as weeks-long courses; treat as hypothesis.Some rapid responders described in clinical abstracts, but not broad RCT-grade evidence.
Main tradeoffPotential upside comes with much more safety and screening caution than lower-risk alternatives.Evidence and product availability can still be uneven, so documentation matters more than hype.

03 · Safety & restrictions

Decision factorEpitalonSelank
Adverse effectsSparse modern safety datasets; high uncertainty.Limited Western regulatory data; higher scrutiny warranted.
ContraindicationsNo established data.No established label.
Interaction notesUnknown.Animal diazepam interaction explored; do not translate to human guidance.
Regulatory statusNot approvedNot approved
FDA flagFDA status unclearFDA compounding caution
WADA statusNot listedStatus unclear

04 · Age & monitoring

Decision factorEpitalonSelank
Supported age ranges35-44, 45-54, 55-64, 65+No age guidance yet
Life-stage noteUsually discussed in older-adult longevity and sleep-maintenance contexts, not younger performance use.Not yet documented
Monitoring burdenNot specifiedNot specified
Follow-up cadenceNot yet documentedNot yet documented

05 · Cost & sourcing

Decision factorEpitalonSelank
Typical cycle cost$59.98€20.64
Estimated monthly cost$79.97€27.52
Cost confidenceHigh confidenceHigh confidence

06 · Before you buy

Decision factorEpitalonSelank
Tracked vendor listings3 listings3 listings
Sourcing noteTracked product pages exist, but naming differences mean the listing needs an extra read before purchase.Product format varies by listing, so double-check route, concentration, and presentation.
Stack-friendly?Usually stack-friendlyUsually stack-friendly

Sources and review notes

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15

    Used for FDA compounding-risk context and peptide safety flags.

  2. The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15

    Used for athlete-facing WADA risk and peptide-class restrictions.

  3. Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15

    Used for broad peptide-therapeutics background and evidence framing.

Still deciding

Get a plan tailored to you.

The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.